International Journal of Drug Discovery and Medical Research <p><span style="color: #333333; font-family: 'Open Sans', sans-serif; font-size: 13px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">International Journal of drug discovery and medical research (Int J drug discov medi research) is an international peer review quarterly, scientific online Journal. This Journal publishes original research work that contributes significantly scientific knowledge in medical sciences, pharmaceutical sciences including all branch of subject like Pharmaceutical Technology, Pharmacology, clinical pharmacology, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmaceutics Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics, Pharmaceutical Analysis, Pharmacognosy, Natural Product Research, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics, Pharmacoeconomics, and Biotechnology etc..</span></p> en-US Mon, 28 Nov 2022 10:57:57 -0500 OJS 60 RECENT ADVANCES IN INDAZOLE-BASED DERIVATIVES OF VEGFR-2 KINASE INHIBITORS AS AN ANTI-CANCER AGENT <p>Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Cancer continues increasing a serious threat to a people health. Cancer is the uncontrolled growth of abnormal cells in the body; cancer develops when the body’s normal control mechanism stops working. Many anti-cancer agents have been developed in recent year but survival rate does not satisfy. Therefore, through many efforts to develop novel anti-cancer agents to cover up for deficiency. Indazole is class of heterocyclic bioactive compounds, making structural modification on active indazole derivatives giving a variety of biological activities such as anti-depressant and antitumor anti-bacterial, anti-inflammatory, anti- hypertensive. These study through various literature focus on recent research of indazole derivatives as an anti-cancer will be useful for further development of Indazole base derivatives with new scaffold and high potency as anti-cancer agent. Recently many efforts have been taken for the development of indazole derivatives as vascular endothelial growth factor-2 (VEGFR-2) kinase inhibitors give good anti-tumor activities. Vascular endothelial growth factor-2 plays a role in tumor angiogenesis. Newly synthesized 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl) acetamide derivatives were designed as VEGFR-2 inhibitors based on scaffold hopping strategy. These compounds exhibited the excellent inhibitory in both vegfr-2 and tumor cells proliferation.&nbsp; A novel vegfr2 inhibitor CHMFL-VEGFR2-002 showed high selectivity among structurally closed kinases including PDGFRs, FGFRs, CSF1R etc.&nbsp; CHMFL-VEGFR2-002 given potent inhibitory activity against VEGFR2 kinase.&nbsp; CHMFL-VEGRF2-002 as a research tool for developing new function of VEGFR2 kinase as well as a potential antiangiogenetic agent for the cancer therapy.</p> Vandana Yadav , Pinkal Patel Copyright (c) 2022 Mon, 28 Nov 2022 00:00:00 -0500